why choose us

Clinical Trials Search

Showing 20,170 of 132,963 result(s)
Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia

Status: Completed

Condition: Acute Myeloblastic Leukemia

Interventions:

Date: 2022-08-10

Bioactive Surfaces vs. Conventional Surfaces in Implants Placed in Atrophic Maxilla With Simultaneous Sinus Lift

Status: Completed

Condition: Edentulous; Alveolar Process, Atrophy

Interventions: when residual bone height is >4 mm sinus lift through crestal approach procedure will be performed and after sinus flor elevation, OSSIX® Bone will

Date: 2022-08-10

Impact of Gastric Length of Myotomy During POEM on Gastroesophageal Reflux

Status: COMPLETED

Condition: Gastric Reflux

Interventions: POEM is a form of natural orifice transluminal endoscopic surgery that is completed by creating a submucosal tunnel in the lower part of esophagus to

Date: 2022-08-10

Ventilatory Effects of THRIVE During EBUS

Status: COMPLETED

Condition: Hypercapnia

Interventions: 2 different rates of nasal flow compared to each other and a baseline of level of nasal oxygen

Date: 2022-08-10

Phase 1b;2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Status: Completed

Condition: Renal Cell Carcinoma

Interventions: Given by IV (vein)

Date: 2022-08-10

Forehead Temperature-Regulating Therapy for Insomnia in Adults With Tourette's Disorder

Status: Completed

Condition: Tourette's Disorder

Interventions: A forehead thermal therapy device will be used nightly for the duration of each sleep period for four weeks.
This device includes a bedside unit

Date: 2022-08-10

ETHAN - ET for Male BC

Status: Completed

Condition: Male Breast Cancer

Interventions: Taken orally

Date: 2022-08-10

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Status: Completed

Condition: Endometrioid Cancer

Interventions:

Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).

Date: 2022-08-09

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

Status: NOT_YET_RECRUITING

Condition: Clostridium Difficile Infection Recurrence

Interventions: 1 probiotic capsule to be taken orally once a day, with breakfast, once a day for 8 weeks.

Date: 2022-08-09

Polatuzumab Vedotin With R-GDP in Relapsed;Refractory Diffuse Large B-cell Lymphoma

Status: Completed

Condition: Diffuse Large B-cell Lymphoma

Interventions: 1.8 mg;kg, intravenous, at day 1, in every 21 days

Date: 2022-08-09